{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:19:12Z","timestamp":1794345552524,"version":"4.9.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2004339"],"award-info":[{"award-number":["NRF-2023R1A2C2004339"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2023R1A2C2006375"],"award-info":[{"award-number":["NRF-2023R1A2C2006375"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["NRF-2019R1A6A1A03032888"],"award-info":[{"award-number":["NRF-2019R1A6A1A03032888"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jhep.2024.10.020","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T11:43:11Z","timestamp":1729510991000},"page":"649-657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2461-6806","authenticated-orcid":false,"given":"Sohyun","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonjeong","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beodeul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-7702","authenticated-orcid":false,"given":"Haeyoun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1132-5217","authenticated-orcid":false,"given":"Jung Sun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Il","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Soo","family":"Kyung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwang-Phill","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-9003","authenticated-orcid":false,"given":"Gwangil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.10.020_bib1","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.10.020_bib2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"The Lancet GastroenterolHepatol"},{"key":"10.1016\/j.jhep.2024.10.020_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib5","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final. Overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib7","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2024.10.020_bib8","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2024.10.020_bib9","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.10.020_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib12","doi-asserted-by":"crossref","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","article-title":"Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in Oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.jhep.2024.10.020_bib13","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib14","first-page":"2854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2024.10.020_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.10.020_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1158\/2159-8290.CD-17-1009","article-title":"Genomic landscape of cell-free DNA in patients with colorectal cancer","volume":"8","author":"Strickler","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.10.020_bib17","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2024.10.020_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100275","article-title":"Cell-free DNA from bile outperformed plasma. as a potential alternative to tissue biopsy in biliary tract cancer","volume":"6","author":"Gou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2024.10.020_bib19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape. and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jhep.2024.10.020_bib20","series-title":"Analytical and clinical validation of a highly sensitive. NGS-based ctDNA assay with real-world concordance in NSCLC","author":"Yi","year":"2024"},{"key":"10.1016\/j.jhep.2024.10.020_bib21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-022-01837-z","article-title":"Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment","volume":"127","author":"Kim","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2024.10.020_bib22","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.12998\/wjcc.v9.i12.2884","article-title":"Detection of EGFR-SEPT14 fusion in cell-free DNA. of a patient with advanced gastric cancer: a case report","volume":"9","author":"Kim","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jhep.2024.10.020_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"Andr\u00e9","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2024.10.020_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer","volume":"19","author":"Li","year":"2017","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.jhep.2024.10.020_bib25","doi-asserted-by":"crossref","first-page":"D862","DOI":"10.1093\/nar\/gkv1222","article-title":"ClinVar: public archive of interpretations of clinically relevant variants","volume":"44","author":"Landrum","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2024.10.020_bib26","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib27","first-page":"1","article-title":"Circulating tumor DNA: an emerging tool in gastrointestinal cancers","volume":"42","author":"Alese","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jhep.2024.10.020_bib28","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2022.40.16_suppl.4009","article-title":"Updated results of the. FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions\/rearrangements","volume":"40","author":"Goyal","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1078-0432.CCR-19-0306","article-title":"Cell-free circulating tumor DNA variant. Allele frequency associates with survival in metastatic cancer","volume":"26","author":"Pairawan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2024.10.020_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA. in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2024.10.020_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jhep.2024.10.020_bib32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2024.10.020_bib33","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.4143\/crt.2022.1450","article-title":"ARID1A mutation from targeted next-generation sequencing predicts primary resistance to gemcitabine and cisplatin chemotherapy in advanced biliary tract cancer","volume":"55","author":"Lee","year":"2023","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.jhep.2024.10.020_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib35","article-title":"Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jhep.2024.10.020_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01672-5","article-title":"Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer","volume":"8","author":"Han","year":"2023","journal-title":"Sig Transduct Target Ther"},{"issue":"224","key":"10.1016\/j.jhep.2024.10.020_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"19;6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824026412?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824026412?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:20:43Z","timestamp":1773451243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824026412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0168827824026412"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.10.020","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}